[A19-62] Pembrolizumab (squamous NSCLC, combination chemotherapy) - Addendum to commission A19-31
Last updated 19.09.2019
Commission awarded on 05.08.2019 by the Federal Joint Committee (G-BA).
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults
PD-L1 expression < 50%: indication of major added benefit. PD-L1 expression ≥ 50%: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.